Total Compensation FY2025
—
As reported in 2026 DEF 14A proxy filing with the SEC
Compensation Breakdown
Base Salary
$1.4M
0% of total
Stock Awards
—
0% of total
Bonus
—
0% of total
Other Compensation
—
0% of total
About Michael Mahoney
Michael Mahoney has served as Boston Scientific's CEO since 2012, growing the medical device company significantly.
Data Source: Compensation figures are sourced from Boston Scientific's DEF 14A proxy statement filed with the U.S. Securities and Exchange Commission (SEC) via EDGAR. Figures reflect total compensation for FY2025 as reported in the Summary Compensation Table.